Scynexis, Inc.: Drug Recall
Recall #D-0042-2024 · 09/25/2023
Class I: Dangerous
Recall Details
- Recall Number
- D-0042-2024
- Classification
- Class I
- Product Type
- Drug
- Recalling Firm
- Scynexis, Inc.
- Status
- Completed
- Date Initiated
- 09/25/2023
- Location
- Jersey City, NJ, United States
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 17,376
Reason for Recall
Cross Contamination with Other Products: Potential cross-contamination of ibrexafungerp citrate drug substance with ezetimibe (a non-antibacterial beta-lactam compound).
Product Description
BREXAFEMME (Ibrexafungerp) tablets 150 mg, 4 count cartons, Rx Only, Manufactured for and distributed by SCYNEXIS, Inc., Jersey City, NJ 07302 NDC 75788-115-04
Distribution Pattern
Nationwide in the US.
Data from FDA openFDA enforcement reports. This site is not affiliated with or endorsed by the FDA. Recall information may be updated by the FDA at any time.